Schedule a meeting to discuss your complex biologic or bioconjugate program with our experts during DCAT Week 2024 , March 18-21.
Abzena has a meeting room at the Lotte Palace and welcomes the opportunity to schedule some time to connect on your project-specific needs and to provide you with an update on our expanded global capabilities. From antibodies (mAbs) to recombinant vaccines and bioconjugates- including ADCs, radioconjugates, and oligonucleotides, our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone.
Our team of experienced experts will include:
- CEO, Matt Stober
- CSO, Dr Campbell Bunce
- CCO, Joseph Principe
- SVP & Scientific Leader, Dr Petra Dieterich
- SVP of Strategy, Ali Kazzaz
- SVP of Global Marketing, Kimberly Burrell
- VP of Cell Line Development, Simon Keen
- Head of US Business Development, Barbara Arnold
- VP of Strategy, Gavin Murdoch
- VP of Business Development for the NE, Joeseph Letizia
Schedule a Meeting with Our Team!
Kick-off DCAT Week 2024 with Abzena! Mix and mingle with industry colleagues on Monday night at the Pharma Industry Outlook Reception!
Abzena will be the sponsor for the Pharma Industry Outlook with Networking Reception taking place on Monday, March 18th from 4:30-6pm. So come and meet our team while enjoying some tasty beverages and canapes.
Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.